Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: Implications for MDMA neurotoxicity

Journal of Neurochemistry

Volumn 112, Issue 4, 2010, Pages 951-962

  Biezonski, Dominik K ^a   Meyer, Jerrold S ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

3,4 methylenedioxymethamphetamine; Neurodegeneration; Neurotoxicity; Serotonin; Serotonin transporter; Vesicular monoamine transporter 2

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN TRANSPORTER; SODIUM CHLORIDE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN LEVEL; BRAIN REGION; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HIPPOCAMPUS; IMMUNOBLOTTING; MALE; MEDIAN RAPHE NUCLEUS; NERVE FIBER TRANSECTION; NEUROTOXICITY; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

5,7-DIHYDROXYTRYPTAMINE; ANIMALS; AREA UNDER CURVE; BENZYLAMINES; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HALLUCINOGENS; MALE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTOXICITY SYNDROMES; NEUROTRANSMITTER UPTAKE INHIBITORS; PREGNANCY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTOSOMES; TIME FACTORS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

ANIMALIA; RATTUS;

EID: 75149150916     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06515.x     Document Type: Article

References (60)

1. Adori C., Andó R. D., Kovács G. G. Bagdy G. (2006) Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in dark agouti rat: temporal, spatial, and cellular patterns. J. Comp. Neurol. 497, 251 269.
2. Aguirre N., Barrionuevo M., Ramírez M. J., Del Río J. Lasheras B. (1999) Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. Neuroreport 10, 3675 3680.
3. Banken J. A. (2004) Drug abuse trends among youth in the United States. Ann. NY Acad. Sci. 1025, 465 471.
4. Battaglia G., Sharkey J., Kuhar M. J. de Souza E. B. (1991) Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography. Synapse 8, 249 260.
5. Baumann M. H., Wang X. Rothman R. B. (2007) 3,4- Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology 189, 407 424.
6. Bhide N S., Lipton J. W., Cunningham J. I., Yamamoto B. K. Gudelsky G. A. (2009) Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain. Brain Res. 1286, 32 41.
7. Booze R. M., Hall J. A., Cress N. M., Miller G. D. Davis J. N. (1988) DSP-4 treatment produces abnormal tyrosine hydroxylase immunoreactive fibers in rat hippocampus. Exp. Neurol. 101, 75 86.
8. Carneiro A. M. Blakely R. D. (2006) Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J. Biol. Chem. 281, 24769 24780.
9. Ciliax B. J., Heilman C., Demchyshyn L. L., Pristupa Z. B., Ince E., Hersch S. M., Niznik H. B. Levey A. I. (1995) The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci. 15, 1714 1723.
10. Descarries L., Berthelet F., Garcia S. Beaudet A. (1986) Dopaminergic projection from nucleus raphe dorsalis to neostriatum in the rat. J. Comp. Neurol. 249, 511 520.
11. De Silva D. J., French S. J., Cheung N. Y., Swinson A. K., Bendotti C., Rattray M. (2005) Rat brain serotonin neurones that express neuronal nitric oxide synthase have increased sensitivity to the substituted amphetamine serotonin toxins 3,4-methylenedioxymethamphetamine and p-chloroamphetamine. Neuroscience 134, 1363 1375.
12. Eravci M., Fuxius S., Broedel O., Weist S., Krause E., Stephanowitz H., Schluter H., Eravci S. Baumgartner A. (2008) The whereabouts of transmembrane proteins from rat brain synaptosomes during two-dimensional gel electrophoresis. Proteomics 8, 1762 1770.
13. Fritschy M. J. Grzanna R. (1992) Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: Compensatory response to neurotoxin-induced cell death in the adult rat brain. J. Comp. Neurol. 321, 421 441.
14. Fritschy M. J., Geffard M. Grzanna R. (1990) The response of noradrenergic axons to systemically administered DSP-4 in the rat: an immunohistochemical study using antibodies to noradrenaline and dopamine-beta-hydroxylase. J. Chem. Neuroanat. 3, 309 321.
15. Green A. R., Mechan O. A., Elliott J. M., O'Shea E. Colado M. I. (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol. Rev. 55, 463 508.
16. Hallett P. J., Collins T. L., Standaert D. G. Dunah A. W. (2008) Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking. Curr. Protoc. Neurosci. 42, 1.16.1 1.16.16.
17. Hansen J. P., Riddle E. L., Sandoval V., Brown J. M., Gibb J. W., Hanson G. R. Fleckenstein A. E. (2002) Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J. Pharmacol. Exp. Ther. 300, 1093 1100.
18. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
19. Jaim-Etcheverry G. Zieher L. M. (1980) DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats. Brain Res. 188, 513 523.
20. Jayanthi L. D., Samuvel D. J., Blakely R. D. Ramamoorthy S. (2005) Evidence for biphasic effects of protein kinase C on serotonin transporter function, endocytosis, and phosphorylation. Mol. Pharmacol. 67, 2077 2087.
21. Kabani N. J., Reader T. A. Dykes R. W. (1990) Monoamines and their metabolites in somatosensory, visual, and cingulate cortices of adult rat: differences in content and lack of sidedness. Neurochem. Res. 15, 1031 1036.
22. Kirilly E., Molnar E., Balogh B., Kantor S., Hansson S. R., Palkovits M. Bagdy G. (2008) Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days. Int. J. Neuropsychopharmacol. 11, 795 809.
23. Kish S. J., Furukawa Y., Chang L. J., Tong J., Ginovart N., Wilson A., Houle S. Meyer J. H. (2005) Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl. Med. Biol. 32, 123 128.
24. Kita T., Wagner G. C. Nakashima T. (2003) Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J. Pharmacol. Sci. 92, 178 195.
25. Kitahama K., Geffard M., Araneda S., Arai R., Ogawa K., Nagatsu I. Pequignot J. M. (2007) Localization of L-DOPA uptake and decarboxylating neuronal structures in the cat brain using dopamine immunohistochemistry. Brain Res. 1167, 56 70.
26. Kovács G. G., Andó R. D., Adori C., Kirilly E., Benedek A., Palkovits M. Bagdy G. (2007) Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in dark agouti rat brain and spinal cord. Neuropathol. Appl. Neurobiol. 33, 193 203.
27. 3H] norepinephrine from rat cortical slices. J. Pharmacol. Exp. Ther. 231, 131 136.
28. Li S. X., Li J., Wang X., Peng Z. G., Kuang W. H. Huang M. S. (2006) Long-term neurotoxic effects of MDMA result in cortical and hippocampal structural changes. Sheng Li Xue Bao 58, 34 40.
29. Livak K. J. Schmittgen T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402 408.
30. Miller G. W., Staley J. K., Heilman C. J., Perez J. T., Mash D. C., Rye D. B. Levey A. I. (1997) Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann. Neurol. 41, 530 539.
31. Miller G. W., Erickson J. D., Perez J. T., Penland S. N., Mash D. C., Rye D. B. Levey A. I. (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 156, 138 148.
32. Molliver M. E., Berger U. V., Mamounas L. A., Molliver D. C., O'Hearn E. Wilson M. A. (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann. NY Acad. Sci. 600, 649 661.
33. O'Callaghan J. P. Miller D. B. (1993) Quantification of reactive gliosis as an approach to neurotoxicity assessment, in NIDA Research Monographs, Vol. 136: Assessing Neurotoxicity of Drugs of Abuse (Erinoff L., ed.), pp. 188 212. DHHS Pub. No. 93-3644. Supt. of Docs., U.S. Govt. Print. Off., Washington, DC.
34. O'Hearn E., Battaglia G., De Souza E. B., Kuhar M. J. Molliver M. E. (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neurosci. 8, 2788 2803.
35. Oleskevich S. Descarries L. (1990) Quantified distribution of the serotonin innervation in adult rat hippocampus. Neuroscience 34, 19 33.
36. Oleskevich S., Descarries L. Lacaille J. C. (1989) Quantified distribution of the noradrenaline innervation in the hippocampus of adult rat. J. Neurosci. 9, 3803 3815.
37. Partilla J. S., Dempsey A. G., Nagpal A. S., Blough B. E., Baumann M. H. Rothman R. B. (2006) Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J. Pharmacol. Exp. Ther. 319, 237 246.
38. Paxinos G. Watson C. (1998) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
39. Piñeyro G. Blier P. (1999) Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 51, 533 591.
40. Piper B. J., Fraiman J. B. Meyer J. S. (2005) Repeated MDMA ('Ecstasy') exposure in adolescent male rats alters temperature regulation, spontaneous motor activity, attention, and serotonin transporter binding. Dev. Psychobiol. 47, 145 157.
41. 1A receptor agonist. J. Pharmacol. Exp. Ther. 317, 838 849.
42. Pranzatelli R. M. Martens M. J. (1992) Plasticity and ontogeny of the central 5-HT transporter: effect of neonatal 5,7-dihydroxytryptamine lesions in rat. Brain Res. Dev. Brain Res. 70, 191 195.
43. Pubill D., Canudas A. M., Pallàs M., Camins A., Camarasa J. Escubedo E. (2003) Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch. Pharmacol. 367, 490 499.
44. Qian Y., Melikian H. E., Rye D. B., Levey A. I. Blakely R. D. (1995) Identification and characterization of antidepressant-sensitive serotonin transporter proteins using site-specific antibodies. J. Neurosci. 15, 1261 1274.
45. Ramamoorthy S. Blakely R. D. (1999) Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285, 763 766.
46. Rattray M., Baldessari S., Gobbi M., Mennini T., Samanin R. Bendotti C. (1996) p-Chlorphenylalanine changes serotonin transporter mRNA levels and expression of the gene product. J. Neurochem. 67, 463 472.
47. Reader T. A., Dewar K. M. Grondin L. (1989) Distribution of monoamines and metabolites in rabbit neostriatum, hippocampus and cortex. Brain Res. Bull. 23, 237 247.
48. Reveron M. E., Monks T. J. Duvauchelle C. L. (2005) Age-dependent (+)MDMA-mediated neurotoxicity in mice. Neurotoxicology 26, 1031 1040.
49. Ricaurte G. A., Yuan J. McCann U. D. (2000) (+/-)3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42, 5 10.
50. Schmidt C. J. Taylor V. L. (1987) Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem. Pharmacol. 36, 4095 4102.
51. Sharma H. S. Ali S. F. (2008) Acute administration of 3,4-methylenedioxymethamphetamine induces profound hyperthermia, blood-brain barrier disruption, brain edema formation, and cell injury. Ann. N Y Acad. Sci. 1139, 242 258.
52. Stone D. M., Merchant K. M., Hanson G. R. Gibb J. W. (1987) Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26, 1677 1683.
53. 3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J. Pharmacol. Exp. Ther. 260, 427 436.
54. Towle A. C., Breese G. R., Mueller R. A., Coyle S. Lauder J. M. (1984) Early postnatal administration of 5,7-DHT: effects on serotonergic neurons and terminals. Brain Res. 310, 67 75.
55. UNODCC (United Nations Office of Drug Control & Crime 2008) World Drug Report. United Nations, New York, NY. ISBN: 978-9211482294
56. Vertesa R. P. Linley S. B. (2007) Comparison of projections of the dorsal and median raphe nuclei, with some functional considerations. Int. Congr. Ser. 1304, 98 120.
57. Wang X., Baumann M. H., Xu H. Rothman R. B. (2004) 3,4- Methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 53, 240 248.
58. Wang X., Baumann M. H., Xu H., Morales M. Rothman R. B. (2005) (+/-)-3,4 Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. J. Pharmacol. Exp. Ther. 314, 1002 1012.
59. Wang X., Baumann M. H., Dersch C. M. Rothman R. B. (2007) Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan. Neuroscience 148, 212 220.
60. Xie T., Tong L., McLane M. W., Hatzidimitriou G., Yuan J., McCann U. Ricaurte G. (2006) Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology 31, 2639 2651.